Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Arzoxifene · 6 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Arzoxifene | DRUG | 20 mg, oral, tablet, once a day for 52 weeks |
| Raloxifene | DRUG | 60 mg, oral, tablet, once a day for 52 weeks |
| Placebo | DRUG | oral, tablet, once a day for 36 months |
| arzoxifene hydrochloride | DRUG | - |
Inclusion Criteria: * Must have osteoporosis * Must be between 50 and 75 years old and be able to walk * Have at least two of your back bones that can be x-rayed * Have not had a period in at least two years * Be willing to have blood tests Exclusion Criteria: * Have a bone disease other than ost...
Arzoxifene is an investigational small molecule being studied for postmenopausal osteoporosis, postmenopausal bone loss, ovarian cancer, and endometrial cancer. It is developed by Eli Lilly and Company (LLY). The drug has been evaluated in clinical trials, but it is not approved and remains in clinical development.
Arzoxifene is a selective estrogen receptor modulator (SERM) that targets estrogen receptors. It is being studied for its effects on bone mass and the uterus in postmenopausal women, as well as for hormone therapy in endometrial and ovarian cancers.
Arzoxifene is developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug has been studied in clinical trials for osteoporosis, postmenopausal bone loss, ovarian cancer, and endometrial cancer.
Arzoxifene has completed Phase 2 and Phase 3 clinical trials. It is not FDA approved and remains an investigational drug. The most advanced trial was a Phase 3 study of its effects on bone mass and the uterus in postmenopausal bone loss.
Arzoxifene has been studied in four completed trials. NCT00085956 was a Phase 3 study of bone mass and the uterus in postmenopausal bone loss. NCT00767299 was a Phase 2 study in Korean women with osteoporosis. NCT00003669 and NCT00003670 were Phase 2 studies in endometrial and ovarian cancer.
Arzoxifene is the active drug, and Arzoxifene Hydrochloride is the salt form used in clinical trials. The trials NCT00003669 and NCT00003670 evaluated Arzoxifene Hydrochloride in endometrial and ovarian cancer, while other studies used Arzoxifene.